Attached files

file filename
EX-99.1 - PROLOR Biotech, Inc.v183140_ex99-1.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities and Exchange Act of 1934
 

Date of Report (Date of earliest event reported):  May 3, 2010
 

PROLOR BIOTECH, INC.

(Exact Name of Registrant as Specified in Its Charter)
 
 
Nevada
 
000-52691
 
20-0854033
(State or Other Jurisdiction of Incorporation)
 
(Commission File Number)
 
(IRS Employer Identification No.)

 
3 Sapir Street
Weizmann Science Park
Nes-Ziona, Israel 74140
(Address of Principal Executive Office)

 
Registrant’s telephone number, including area code (866) 644-7811
 
 

(Former Name or Former Address, if Changed Since Last Report)
 
 
Check the appropriate  box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 


 
 
 
 
ITEM 7.01.
Regulation FD Disclosure.
 
On May 3, 2010, PROLOR Biotech, Inc., a Nevada corporation (the “Company”), issued a press release announcing certain new preclinical data that will be discussed by the Company’s management at the 2010 BIO International Convention in Chicago, as well as at the upcoming Rodman & Renshaw 6th Annual Global Healthcare Conference in London and the Jefferies 2010 Global Life Sciences Conference in New York City. A copy of the press release is furnished hereto as Exhibit 99.1 and incorporated by reference in this Item 7.01.

The information contained in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” with the Securities and Exchange Commission nor incorporated by reference in any registration statement filed by the Company under the Securities Act.

ITEM 9.01. 
Financial Statements and Exhibits.
 
 
(d)  Exhibits.
 
 
Exhibit Number
 
Description
 
99.1
 
Press Release dated May 3, 2010.

 
 

 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
PROLOR BIOTECH, INC.
Date:  May 3, 2010
 
By:  /s/ Shai Novik

Shai Novik
President


 

 
 

 
 
EXHIBIT INDEX
 
Exhibit Number
 
Description
99.1
 
Press Release dated May 3, 2010.